Guided Therapeutics (GTHP) Amortization of Deferred Charges (2018 - 2025)

Guided Therapeutics has disclosed Amortization of Deferred Charges across 8 years of filings, most recently posting $55000.0 for Q4 2025.

• Amortization of Deferred Charges for Q4 2025 came in at $55000.0, up 44.74% year-over-year; the trailing twelve-month figure through Dec 2025 was $244000.0 (up 121.82% YoY), and the FY2025 annual result was $244000.0, up 121.82% from the prior year.
• Amortization of Deferred Charges came in at $55000.0 for Q4 2025 at Guided Therapeutics, up from $54000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $172000.0 in Q2 2021 to a low of $14000.0 in Q3 2021.
• The 5-year median for Amortization of Deferred Charges is $35000.0 (2022), against an average of $47350.0.
• Across the five-year window, Amortization of Deferred Charges sank 86.41% in 2021 and soared 277.78% in 2025, its largest moves.
• Guided Therapeutics' Amortization of Deferred Charges stood at $70000.0 in 2021, then plunged by 54.29% to $32000.0 in 2022, then rose by 3.12% to $33000.0 in 2023, then increased by 15.15% to $38000.0 in 2024, then surged by 44.74% to $55000.0 in 2025.
• The last three Amortization of Deferred Charges figures came in at $55000.0 (Q4 2025), $54000.0 (Q3 2025), and $68000.0 (Q2 2025), per Business Quant data.